CONQUEST is proud to be a sponsor of the EUSTAR Course 2025, which took place from February 6-8 in Bordeaux, France. Dr. Gregory Gordon, Chief Medical Officer of the Scleroderma Research Foundation (SRF), represented the SRF at this key event, where experts in scleroderma research gathered to discuss the latest advancements.
The European Scleroderma Trials and Research Group (EUSTAR) is an international research network consisting of over 200 scleroderma centers. Since its founding in 2004, EUSTAR has played a crucial role in advancing scleroderma research.
“It was an honor to represent SRF and the CONQUEST clinical study at the EUSTAR Course this year. EUSTAR gathers physicians from the leading research centers in Europe, and their research affects the care of scleroderma patients throughout the world,” Dr. Gordon says. “SRF was excited to be able to take part in the meeting this year.”
Launched in April 2024, CONQUEST was developed with input from partner biopharmaceutical companies to accelerate the development of scleroderma treatment options. With 90 clinical trial sites open in 20 countries, individuals with interstitial lung disease associated with systemic sclerosis (SSc-ILD) who qualify for the trial can now enroll in sites across the world.
Through its global network of scleroderma treatment centers, CONQUEST aims to make a widespread impact on scleroderma research, with plans to enroll 430 patients in its first iteration.
Pictured: Dr. Gregory Gordon and Dr. Dinesh Khanna, Co-Chair of the CONQUEST Steering Committee
